Cel The ultimate goal we seek in ASTHMAPOC project is to develop a “ready to the market” point-of-care disposable device for self-patient management of chronic asthma. According to WHO statistics more than 235 million people suffer from asthma worldwide. As for all other chronic diseases, effective management of asthma is full of challenges because of the difficulties in determining the appropriate treatment programs and the low adherence to control medications. This typically results in many patients non-effectively prevented from asthma exacerbations and the consequent unnecessary too often visits to emergencies. ASTHMAPOC aims providing a low-cost affordable solution to chronic asthmatic patients for self-management of their disease. Patients who self-test can have a better control over their chronic condition, and make therapeutic, behavioral, and environmental adjustments in accordance with advice from healthcare professionals. Our approach to achieve ASTHMAPOC goals is to develop a point-of-care device based on disposable electrochemical biosensors capable to determine the concentration of FENO (fractional exhaled nitric oxide). FENO emerged in the last decade as an important biomarker for asthma assessment and management. The clinical utility of FENO has been already validated to the extent that currently there are approved standards in US and EU (further details will be provided in section 1.3). However, only few point-of-care devices have been developed for clinical use (section 1.4) while there is no single product for self-patient management in the market. This niche market is the one we seek exploring with ASTHMAPOC, but in order to be successful in this market we need first to carry out an in-depth feasibility study. Dziedzina nauki engineering and technologyelectrical engineering, electronic engineering, information engineeringelectronic engineeringsensorsbiosensorsmedical and health sciencesclinical medicinepneumologyasthmanatural scienceschemical scienceselectrochemistrymedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs Program(-y) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Temat(-y) PHC-12-2014-1 - Clinical research for the validation of biomarkers and/or diagnostic medical devices Zaproszenie do składania wniosków H2020-SMEInst-2014-2015 Zobacz inne projekty w ramach tego zaproszenia Szczegółowe działanie H2020-SMEINST-1-2014 System finansowania SME-1 - SME instrument phase 1 Koordynator INSPIRALIA SOCIEDAD LIMITADA Wkład UE netto € 50 000,00 Adres CALLE MANUEL TOVAR 49 28034 Madrid Hiszpania Zobacz na mapie MŚP Organizacja określiła się jako MŚP (firma z sektora małych i średnich przedsiębiorstw) w czasie podpisania umowy o grant. Tak Region Comunidad de Madrid Comunidad de Madrid Madrid Rodzaj działalności Private for-profit entities (excluding Higher or Secondary Education Establishments) Linki Kontakt z organizacją Opens in new window Strona internetowa Opens in new window Uczestnictwo w unijnych programach w zakresie badań i innowacji Opens in new window sieć współpracy HORIZON Opens in new window Koszt całkowity € 71 429,00
